# IVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies

> **NCT04033276** · PHASE4 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 50 (actual)

## Conditions studied

- Renal Transplant

## Interventions

- **DRUG:** Rituximab
- **DRUG:** intravenous immune globulin

## Key facts

- **NCT ID:** NCT04033276
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-08
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-05-03
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2022-10-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04033276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04033276, "IVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04033276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*